Previously, we showed that Src tyrosine kinases are activated early in the development of human colon cancer and are suppressed as intestinal cells differentiate. We identified RACK1 as an endogenous substrate, binding partner and inhibitor of Src. Here we show (by overexpressing RACK1, depleting Src or RACK1 and utilizing cell-permeable peptides that perturb RACK1's interaction with Src) that RACK1 regulates growth of colon cells by suppressing Src activity at G 1 and mitotic checkpoints, and consequently delaying cell cycle progression. Activated Src rescues RACK1-inhibited growth of HT-29 cells. Conversely, inhibiting Src abolishes growth promoted by RACK1 depletion in normal cells. Two potential mechanisms whereby RACK1 regulates mitotic exit are identified: suppression of Src-mediated Sam68 phosphorylation and maintenance of the cyclin-dependent kinase (CDK) 1-cyclin B complex in an active state. Our results reveal novel mechanisms of cell cycle control in G 1 and mitosis of colon cells. The significance of this work lies in the discovery of a mechanism by which the growth of colon cancer cells can be slowed, by RACK1 suppression of an oncogenic kinase at critical cell cycle checkpoints. Small molecules that mimic RACK1 function may provide a powerful new approach to the treatment of colon cancer.
Introduction
We and others showed that the specific activity of Src tyrosine kinases is elevated in most malignant and premalignant lesions of the colon, and decreases as normal intestinal cells differentiate (reviewed by Cartwright, 1998) . Activated Src is oncogenic (reviewed by Thomas and Brugge, 1997; Bromann et al., 2004) .
Together, these results suggest that downregulation of Src activity is important for differentiation, and upregulation is important for growth and transformation of colon cells. Thus, identifying mechanisms that regulate Src activity in colon cells may provide clues about how normal cells regulate their growth and how loss of that regulation results in uncontrolled growth and malignant transformation.
RACK1 is the founding member of a family of intracellular receptors for activated protein kinase C (PKC) collectively called RACKs (reviewed by Dorn and Mochly-Rosen, 2002 ). We identified RACK1 as an endogenous substrate, binding partner and inhibitor of Src tyrosine kinases (Chang et al., 1998 (Chang et al., , 2001 (Chang et al., , 2002 Mamidipudi et al., 2004a, b) .
Cancer genes exert their greatest effect on the cell cycle by targeting regulators of the G 1 checkpoint. Once cells pass this checkpoint, they are fated to synthesize DNA and divide. Cancer cells subvert controls at work at this restriction point and remain in cycle. G 1 /S transition is controlled by two key families of proteins: cyclin-dependent kinases (CDKs) and cyclins. Cyclins bind to and activate CDKs. Another critical event in cell cycle progression at G 1 /S is phosphorylation and inactivation of the retinoblastoma protein (pRb) and release of regulatory proteins such as E2F, which stimulate transcription of target genes that are required for the S phase entry and DNA replication. v-Src, the transforming homolog of c-Src, directly influences cell cycle proteins that regulate G 1 /S transition (Thomas and Brugge, 1997; Riley et al., 2001) . For example, in fibroblasts, v-Src induces rapid transit through the G 1 checkpoint by simultaneously suppressing the CDK inhibitor p27 and inducing cyclins D1, E and A.
Sam68, a member of the STAR family of RNAbinding proteins, is a mitotic-specific substrate of Src (reviewed by Lukong and Richard, 2003) . Conditional overexpression of Sam68 in fibroblasts results in G 1 arrest and apoptosis, the latter of which requires the RNA-binding ability of Sam68 (Taylor et al., 2004) . Similarly, overexpression of Sam68 suppresses cell proliferation induced by the breast tumor kinase (BRK) (Lukong et al., 2005) . Blocking tyrosine phosphorylation of Sam68 appears to promote its antiproliferative functions. For example, inhibiting Src phosphorylation of Sam68 blocks exit of cells from mitosis (Pillay et al., 1996) . Moreover, tyrosine phosphorylation of Sam68 by Src or BRK kinases reduces Sam68's ability to bind RNA (Wang et al., 1995; Derry et al., 2000; Haegebarth et al., 2004) and thereby its ability to induce apoptosis (Taylor et al., 2004) . Thus, downregulation of Sam68 may be important for signaling or transformation by these kinases. Consistent with this possibility is the finding that antisensemediated reduction of Sam68 expression transforms mouse fibroblasts . Together, these data suggest that Sam68 functions as a tumor suppressor by regulating cell cycle progression through G 1 /S and G 2 / M and by inducing apoptosis, and that Src opposes these antiproliferative activities of Sam68.
We hypothesized that RACK1 regulates growth of human colon cells, in part by suppressing Src activity at G 1 and mitotic checkpoints, and consequently delaying cell cycle progression. We found that RACK1 regulates growth of colon cells, in part, by suppressing Src activity in G 1 and mitosis, and thereby delaying passage of cells through G 1 and mitotic checkpoints. Our results suggest a potential role for RACK1-like inhibitors of Src in colon cancer therapy.
Results

RACK1, via its interaction with Src, regulates growth of human colon cells
We hypothesized that RACK1 regulates growth of human colon cells, in part, by suppressing Src kinase activity. To test this, we first expressed green fluorescence protein (GFP)-RACK1 in HT-29 colon carcinoma cells and measured cell growth rates over 6 days ( Figure 1a) . We observed that RACK1-overexpressing cells grew slower than vector-transfected cells. After 3 days of growth, there were approximately threefold fewer RACK1-overexpressing cells than vector-transfected cells. After 4 days, GFP-RACK1 expression decreased (lower panel) and cell growth rate increased. To determine whether RACK1 exerts its inhibitory influence on cell growth via its interaction with Src, we utilized a RACK1 mutant (RACK1 Y228F/Y246F) that lacks the Src phosphorylation and binding sites, and consequently is no longer a substrate, binding partner or inhibitor of Src (Figures 3c, 5a , 7a and Supplementary Figure 1S ; Chang et al., 2001 Chang et al., , 2002 Mamidipudi et al., 2004a, b) . Overexpression of the mutant RACK1 had no effect on cell growth, indicating that RACK1 exerts its inhibitory influence on growth through its interaction with Src. When cell proliferation was measured by the ability of metabolically active cells to reduce Alamar Blue, cells expressing wild-type but not mutant RACK1 proliferated slower than vector-transfected cells (Figure 1b) . In a complementary proliferation assay, 5 HT-29 cells were suspended in McCoy's medium supplemented with 10% FBS and seeded onto 35 mm diameter plates. After 24 h, cells were transfected with 8 mg of pcDNA3-GFP vector, pcDNA3-GFP-RACK1 or pcDNA3-GFPmutant RACK1. Starting 24 h after transfection, cells were counted daily for 6 days and assessed for GFP expression by fluorescence microscopy. GFP expression remained stable until day 4 and then decreased. Data represent mean values7standard errors of the mean (s.e.m.) from triplicate plates and are representative of three independent experiments. , vector; , RACK1; , mutant RACK1. (b) Effect of RACK1 overexpression on cell proliferation. At 24 h after transfection, equal volumes of cells were collected in fresh media containing 10% Alamar Blue for proliferation assays, as described in Materials and methods. x axis, hours incubated; y axis, relative reduction of Alamar Blue. Data represent mean values7s.e.m. from triplicate wells and are representative of two independent experiments. (c) Effect of RACK1 overexpression on Ki-67 expression and cell cycle distribution. At 48 h after transfection with HA-RACK1, HT-29 cells were fixed and stained with FITC-conjugated Ki-67 mAb and PI and analysed by bivariate flow cytometry. x axis, DNA content; y axis, Ki-67-positive cell number. Ki-67-positive cells (in the G 1 , S or G 2 / M phase of the cycle) are located within the box. Ki-67-negative cells (in G 1 ) are located below the box. %, Percentage of cells that are Ki-67-positive. Data are representative of two independent experiments. Lower panels: Lysates containing 20 mg of total cellular protein were subjected to immunoblot analysis with anti-RACK1. V, vector; RK, RACK1; RKm, RACK1 Y228F/Y246F mutant. The molecular mass of HA-RACK1 was consistent with the predicted molecular mass of a RACK1 protein containing nine additional amino acids from the HA tag.
RACK1 regulates colonic cell growth V Mamidipudi et al we used bivariate-flow-cytometric analysis to assess cells for the expression of the nuclear proliferation antigen Ki-67 (which is expressed during G 1 , S, G 2 and M, but not for G 0 ), and for phase of the cell cycle ( Figure 1c) . We observed that twice as many vector or mutant RACK1-overexpressing cells expressed Ki-67 as did wild-type RACK1-overexpressing cells. Collectively, these results suggest that RACK1, in part via its interaction with Src, regulates growth of colon cells.
We hypothesized that depleting Src would have a similar inhibitory effect on growth as does overexpression of Src's endogenous inhibitor RACK1. Thus, in a complementary approach to the RACK1 overexpression studies, we introduced two different src small interfering RNAs (siRNAs) (that we generated from different regions of the src gene) into HT-29 cells and examined their influence on cell growth. We found that Src depletion ( Figure 2a In additional experiments where cell growth was measured for 6 days, Src protein expression and cell growth rates increased after day 4 (data not shown). When proliferation was measured by the ability of metabolically active cells to reduce Alamar Blue, again the Src-depleted cells grew slower than the control cells (Figure 2b ). Finally, bivariate flow cytometric analysis revealed that twice as many vector or untransfected cells expressed Ki-67 as did Src-depleted cells (Figure 2c ). Thus Src depletion, like RACK1 overexpression, inhibits growth of colon cells.
RACK1, via its interaction with Src, regulates G 1 /S progression in colon cells Results from the flow cytometry analyses suggested that RACK1 overexpression prolongs the G 0 /G 1 phase of the colon cell cycle (Figure 1c ). This suggested that RACK1 might regulate the G 1 checkpoint. To test this directly, we synchronized HT-29 cells in G 0 with serum withdrawal for 48 h, released them into G 1 with the addition of serum and analysed cellular DNA content by flow cytometry. Control experiments showed that all transfectants were equivalently synchronized after serum starvation for 48 h (data not shown). After treatment of serum-starved cells for 2 h with 10% serum, approximately half of the vector-transfected cells were in G 1 (47%) and more than a third had entered the S phase (36%), as would be expected for malignant cells (Figure 3a ). In contrast, three-quarters of the RACK1-overexpressing cells remained in G 1 (75%) and few had entered the S phase (17%). Cells expressing the RACK1 mutant progressed through the cell cycle at a rate similar to vector-transfected cells. Thus, RACK1 appears to work through Src to regulate G 1 /S progression.
Next, we examined G 1 /S progression in HT-29 cells transfected with src siRNAs (Figure 3b ). After treatment of serum-starved cells for 2 h with serum, 39% of the vector-transfected cells were in G 1 and 40% had entered the S phase. In contrast, three-quarters or more of the cells expressing src siRNA-5 or siRNA-6 remained in G 1 (75 or 80%, respectively) and few had entered S phase (18 or 13%, respectively). Thus, Src depletion induced a partial G 1 arrest. Interestingly, Srcdepleted cells progressed through the cycle at a rate similar to that of RACK1-overexpressing cells.
RACK1 inhibits key regulators of G 1 /S transition by suppressing Src activity To determine the mechanism by which RACK1 regulates G 1 /S transition, we examined RACK1's effect on the activity of Src and Src-mediated regulators of cell cycle progression at the G 1 /S boundary. To do so, HT-29 transfectants were synchronized in G 0 by serum withdrawal for 48 h and released into G 1 by the addition of serum for 2 h. Overexpression of wild-type but not mutant RACK1 resulted in decreased in vitro kinase activity of Src, CDK4 and CDK2, decreased cyclin D1 expression, induction of the CDK inhibitor p27, dephosphorylation of pRb and sequestration of the transcription factor E2F1 in G 1 (Figure 3c ). Thus, RACK1 overexpression in HT-29 colon carcinoma cells inhibited key regulators of G 1 /S transition by suppressing Src kinase activity. Depleting Src had a similar inhibitory effect on cell cycle regulators in the G 1 phase (Figure 3d ). In a complementary approach to enforced overexpression of RACK1 or depletion of Src, we incubated HT-29 cells with cell-permeable peptides that alter Src activity by selectively disrupting or enhancing Src's interaction with RACK1 (Miller et al., 2004) , and HT-29 cells were transfected with vector, wild-type or mutant GFP-RACK1 (a and c), or vector, src siRNA-5 or src siRNA-6 (b and d), synchronized in G 0 by serum starvation for 48 h, released into G 1 with the addition of 10% FBS for 2 h and analysed for cellular DNA content by flow cytometry (a and b) or for expression and activity of G 1 cell cycle regulators (c and d). For the latter, proteins were precipitated with anti-Src, CDK4 or CDK2 from lysates containing 500 mg of cellular protein and analysed for in vitro protein kinase activity by incubating with [g-32 P]ATP together with MnCl 2 and enolase (Src ips), MgCl 2 and Rb peptide (CDK4 ips) or MgCl 2 and histone H1 (CDK2 ips) for 10 min at 301C, or subjected to immunoblot analysis with anti-Src, CDK4 or CDK2, respectively. Otherwise proteins from lysates containing 20 mg of cellular protein were subjected to immunoblot analysis with antibodies to RACK1, cyclin D1, p27, pRb or E2F1. For each panel shown, data are representative of two or more independent experiments. RACK1 regulates colonic cell growth V Mamidipudi et al measured the effect on cell proliferation (Figure 4a ). Cells incubated with either of two peptides that increase Src activity by disrupting the Src-RACK1 complex (antagonist peptides, bC2-4 or bIIV5-3) grew faster than cells incubated with no peptide or carrier peptide. In contrast, cells incubated with a peptide that inhibits Src activity by enhancing Src's interaction with RACK1 (agonist peptide, bAg) grew slower than other cells.
Next, we analysed the effect of the peptides on activities of Src and Src-mediated cell cycle regulators in G 1 of HT-29 cells. We observed that incubation of G 1 cells with peptides that disrupt the Src-RACK1 complex resulted in increased Src kinase activity, as measured by enolase phosphorylation in vitro, and by Src phosphorylation of Stat3 and induction of Myc in vivo (Figure 4b , lanes 2 and 3). Incubation with these Src-activator peptides also led to induction of cyclins D1, E and A (Figure 4c ), enhanced binding of the cyclins to their CDK partners, suppression of CDK inhibitors p16, p15 and p27 (Figure 4d ), and hyperphosphorylation of Rb and release of E2F1 (Figure 4e ). Incubation of G 1 cells with the peptide that enhances RACK1's interaction with Src had the opposite effect on Src activity and Srcmediated G 1 regulators (lane 4). Together, these results show that RACK1 inhibits key cell cycle regulators of G 1 /S transition by suppressing Src activity.
To determine whether RACK1 regulates growth of colon cells other than HT-29, we transfected WiDr colon carcinoma cells with wild-type or mutant RACK1 and assessed the effect on Src activity and cell growth. Again we observed that wild-type but not mutant RACK1 inhibited the in vitro kinase activity of Src , no peptide (NP); , carrier peptide (c); , bC2-4 antagonist peptide (C2); , bIIV5-3 antagonist peptide (V5); and , bAg agonist peptide (Ag). Data represent mean values7s.e.m. from five wells and are representative of three independent experiments. (b-e) Effect of peptides on key regulators of G 1 /S progression. Cells were synchronized in G 0 , released into G 1 with the addition of 10% FBS for 2 h and incubated with peptide as indicated. Immunoprecipitates were assayed for in vitro kinase activity or subjected to immunoblot analysis as indicated and as described in the legend to Figure 3 . Otherwise, lysate proteins were subjected to immunoblot analysis as indicated. Data are representative of 2-3 independent experiments. RACK1 regulates colonic cell growth V Mamidipudi et al ( Figure 5a ) and the growth of cells (Figure 5c ). Depleting Src with siRNAs had a similar inhibitory effect on Src activity (Figure 5b ) and cell growth (Figure 5d ).
Suppressing Src activity is a major mechanism by which RACK1 regulates growth of colon cells To assess RACK1's influence on growth of normal colon cells, we introduced RACK1 siRNA into human colonic epithelial cells and examined the effect on cell growth (Figure 5e ). Introduction of RACK1 siRNA inhibited RACK1 expression (lower panel) and accelerated cell growth. Treatment with the Src-specific tyrosine kinase inhibitor SU6656 (Blake et al., 2000) abolished growth that was promoted by RACK1 depletion. Conversely, activated Y527F Src rescued growth that was inhibited by RACK1 overexpression in HT-29 cells (Figure 5f ). These results, together with those showing that the RACK1 mutant does not inhibit cell growth (Figures 1, 3 and 5c), demonstrate that suppressing Src activity is a major mechanism by which RACK1 regulates growth of colon cells.
RACK1 negatively regulates exit of cells from mitosis
We hypothesized that Src and its inhibitor RACK1 influence cell cycle progression through G 2 /M, as they do through G 1 /S. We proposed that they do so by regulating two key checkpoints: one in G 2 that controls entry into mitosis and another in mitosis that regulates exit from mitosis. The cyclin B/CDK1 complex is a key regulator of G 2 /M progression (reviewed by Liu et al., 2000; Porter and Donoghue, 2003) . The complex must be activated during G 2 for entry into mitosis, and inactivated during late M phase for exit from mitosis. Thus, we thought that one potential mechanism by which RACK1 regulates G 2 / M progression is by influencing CDK1 activity at these checkpoints.
To assess RACK1's effect on entry into mitosis, we enriched RACK1-overexpressing HT-29 cells in G 2 by treating with aphidicolin, washing and replating in drug-free media for varying time periods, and analysed cellular DNA content by flow cytometry. We observed that RACK1-overexpressing G 2 cells progressed into mitosis at a rate similar to that of vector-transfected cells (data not shown). Thus, RACK1 did not appear to regulate the G 2 checkpoint. Next, we assessed RACK1's influence on mitotic exit by treating with nocodozole for 24 h, then washing and replating in drug-free media for varying time 5 NCM460 human colonic epithelial cells were transfected with non-targeting siRNA (NTsi) or RACK1 siRNA (RKsi) and treated with the Src-specific tyrosine kinase inhibitor SU6656 (SU) where indicated and as described (Miller et al, 2004) . Starting 24 h after transfection, four plates of cells from each transfection were counted daily for 4 days. Fresh SU6656 was added daily. Four independent experiments were performed and the data represent the mean7s.e.m. from the combined experiments. Differences in cell number between RKsi and NTsi or RKsi and RKsi þ SU were significant from day 2-4 (Pp0.001). Lower panel: Lysates containing 20 mg of total cellular protein were subjected to immunoblot analysis with anti-RACK1. (f) Activate Y527F Src rescues RACK1-inhibited growth. A total of 5 Â 10 4 HT-29 cells were transfected with vector (V) or wild-type RACK1 alone (RK) or together with Y527F Src (RK þ Src). Starting 24 h after transfection, four plates of cells from each transfection were counted daily for 4 days. Four independent experiments were performed and the data represent the mean7s.e.m. from the combined experiments. Differences in cell number between RK and RK þ Src were significant from day 2 to 4 (Pp0.01). Lower panel: Lysates containing 20 mg of total cellular protein were subjected to immunoblot analysis with anti-Src. Cells were analysed for GFP expression by fluorescence microscopy with a GFP filter. GFP expression was observed in E80% of cells and remained stable for 3-4 days.
RACK1 regulates colonic cell growth V Mamidipudi et al periods. We observed that after 3 h in drug-free media, many of the vector-or mutant RACK1-expressing cells had progressed into G 1 and S phase (43 and 40%, respectively) (Figure 6a ). In contrast, fewer of the RACK1-overexpressing cells had done so (26%); nearly three-quarters of them remained in the G 2 / M phase (74%). These results suggest that RACK1 negatively regulates mitotic exit, in part via its interaction with Src.
We hypothesized that one mechanism by which RACK1 regulates mitotic exit is by maintaining the cyclin B/CDK1 complex in an active state. To test this, we overexpressed wild-type or mutant RACK1 in HT-29 cells, released cells from a nocodozole-induced mitotic arrest and analysed cyclin B binding to CDK1, and CDK1 kinase activity (Figure 6b ). We observed that overexpression of wild-type but not mutant RACK1 resulted in increased association of CDK1 and cyclin B during late mitosis (second panel, lanes 2 and 5) and, consequently, increased kinase activity of CDK1 (third panel, lanes 2 and 5). These results suggest that RACK1, in part via its inhibitory influence on Src, regulates mitotic exit by maintaining the cyclin B/CDK1 complex in an active state.
Src phosphorylation of Sam68 is required for cells to exit mitosis (Pillay et al., 1996) . Thus, we hypothesized that another mechanism by which RACK1 regulates mitotic exit is by inhibiting Src phosphorylation of Sam68. We found that Src in vitro kinase activity (as measured by phosphorylation of the exogenous substrate enolase; Figure 7a 
RACK1 enhances the RNA-binding activity of Sam68 as cells exit mitosis
The tyrosine phosphorylation of Sam68 by Src family kinases and the nuclear kinase BRK/Sik reduces Sam68's RNA-binding activity (Wang et al., 1995; Derry et al., 2000; Haegebarth et al., 2004) , an activity that is required for Sam68 to induce apoptosis (Taylor et al., 2004) . In light of this, we hypothesized that RACK1, via its inhibitory influence on Src activity, would enhance the RNA-binding activity of Sam68. To test this, we analysed the ability of Sam68 from RACK1-overexpressing HT-29 cells to bind homopolymeric RNAs during mitosis. To do so, lysate proteins from mitotic cells were precipitated with poly(U)-sepharose and subjected to immunoblot analysis with Sam68 ( Figure 7c ). We observed higher levels of Sam68 bound to RNA in RACK1-overexpressing cells than in vector or mutant RACK1-overexpressing cells (Figure 7c , compare lane 2 with lanes 1 and 3). These data suggest that RACK1, in part via its inhibitory influence on Src, enhances the RNA-binding activity of Sam68 during mitosis. and 4) , GFP-RACK1 (lanes 2 and 5) or mutant GFP-RACK1 Y228F/Y246F (lanes 3 and 6) were treated with nocodazole, washed and replated in drug-free media as described in (a). Cells were lysed and CDK1 immunoprecipitates were subjected to immunoblot analysis with anti-cyclin B (top panel) or anti-CDK1 (bottom panel), or assayed for in vitro kinase activity using histone H1 as an exogenous substrate (middle panel). Data are representative of two independent experiments. RACK1 regulates colonic cell growth V Mamidipudi et al
Discussion
Our results demonstrate that RACK1 regulates growth of human colon cells by suppressing Src activity at G 1 and mitotic checkpoints. They reveal novel mechanisms of cell cycle control as colon cells enter the S phase and exit mitosis. The significance of these findings is that an endogenous inhibitor that governs these critical restriction points in the cycle would exert powerful and pervasive control over colonic cell growth. This is the first study to show that RACK1, via its inhibitory influence on Src activity, regulates mitotic exit (Figure 6a ). Our findings are consistent with those of others showing that a selective Src family tyrosine kinase inhibitor, PD173955, causes a potent mitotic arrest by inhibiting the basal activity, as well as the mitotic hyperactivity of Src kinases (Moasser et al., 1999) . Our results reveal two potential mechanisms by which RACK1 regulates mitotic exit: by suppressing Src phosphorylation of Sam68 (Figure 7a and b) and by maintaining the CDK1-cyclin B complex in an active state (Figure 6b) . Finally, our results identify another novel function of RACK1: its ability to enhance the RNA-binding activity of a mitotic substrate of Src, Sam68 (Figure 7c) .
Emerging evidence indicates that Sam68 has antiproliferative properties and that it functions as a tumor suppressor by regulating cell cycle progression through G 1 /S and G 2 /M and by inducing apoptosis (Lukong and Richard, 2003; Taylor et al., 2004) . Moreover, downregulation of Sam68 may be important for signaling or transformation by Src and BRK kinases (Derry et al., 2000; Haegebarth et al., 2004; Lukong et al., 2005) . A major mechanism by these kinases curtail Sam68's antiproliferative activities is by phosphorylating Sam68 on tyrosine, thereby releasing cells from mitosis, accelerating entry into the S phase, inhibiting Sam68 RNA-binding activity and thereby blocking apoptosis. Our findings suggest that RACK1, by controlling Src activity in G 1 and mitosis, safeguards Sam68's tumor suppressor activities in colon cells by regulating entry into the S phase (Figure 3) , exit from mitosis ( Figure 6a ) and cell growth (Figure 1 ). RACK1 also enhances Sam68's RNA-binding activity (Figure 7c ), which is required for Sam68's proapoptotic function (Taylor et al., 2004) . Thus, RACK1 provides checks and balances on oncogenic kinases, both by constraining their proliferative activities and by protecting tumor suppressor functions of their substrates.
Our findings that RACK1, via its inhibitory influence on Src activity, slows the growth of human colon cells (Figure 1 ) by inhibiting cell cycle regulators in G 1 (Figure 3c ) and therefore G 1 /S progression (Figure 3a) are consistent with our previous findings in fibroblasts (Mamidipudi et al., 2004a, b) . New findings are that: (1) Src depletion slows the growth of human colon carcinoma cells by mechanisms similar to those of RACK1 overexpression (Figures 2, 3b and d) , (2) peptides that selectively disrupt or enhance RACK1's interaction with Src alter growth of colon cells (Figure 4) , (3) depleting RACK1 accelerates growth of normal colon cells and this effect can be abolished by inhibiting Src activity ( Figure 5e ) and (4) activated Y527F Src rescues RACK1-inhibited growth of HT-29 cells (Figure 5f ).
The striking effect that RACK1 depletion has on accelerating colonic cell growth (Figure 5e ) could be due to Src-independent functions of RACK1 in growth regulation. However, our findings that: (1) mutant RACK1 does not inhibit growth, (2) peptides that selectively disrupt or enhance RACK1's interaction with Src alter growth, (3) activated Src rescues RACK1- Lysate proteins were subjected to immunoblot analysis with anti-RACK1 or Sam68, or were precipitated with anti-phosphotyrosine and subjected to immunoblot analysis with anti-Sam68, as indicated. Otherwise, lysate proteins were precipitated with anti-Src and assayed for in vitro kinase activity or subjected to immunoblot analysis with anti-RACK1. Peptides: C, carrier; An, bIIV5-3 antagonist; Ag, bAg agonist. (c) Cells were treated with nocodazole, washed and replated in drug-free media as described in the legend to Figure 6 . Poly(U)-binding proteins were precipitated from cell lysates with poly(U)-sepharose and subjected to immunoblot analysis with antiSam68. For each panel shown, data are representative of two or more independent experiments. RACK1 regulates colonic cell growth V Mamidipudi et al inhibited growth and (4) inhibiting Src activity abolishes growth promoted by depleting RACK1, provide strong evidence that a major mechanism by which RACK1 works to regulate growth of colon cells is via its inhibitory influence on Src.
Is RACK1 deregulated in colon cancer cells such that it cannot suppress Src activity to the level of normal colon cells? Such deregulation could occur if: (1) RACK1 is not present in critical subcellular compartments where Src is active, (2) RACK1 is post-translationally modified (e.g. by phosphorylation) such that it can no longer inhibit Src, (3) other protein interactions of RACK1 and/or Src interfere with RACK1 suppression of Src, (4) RACK1 is mutated such that it can no longer inhibit Src activity or (5) endogenous levels of RACK1 are not sufficient to override the striking increase in both Src expression (threefold) and Src-specific activity (4-10-fold) that occurs as cells become malignant (Cartwright et al., 1989 (Cartwright et al., , 1990 Park and Cartwright, 1995) . In support of the latter possibility, we find that RACK1 expression in colon carcinoma cells is similar to that in normal colon cells and is not cell cycle regulated (unpublished results).
Overall, our results signify a potential mechanism by which the growth of colon cancer cells can be slowed, by utilizing RACK1-like inhibitors of oncogenic Src kinases at G 1 and mitotic checkpoints. This discovery reveals a possible new strategy for the treatment of human colon cancer that targets specific protein-protein interactions. Namely, that peptides or small molecule inhibitors that mimic RACK1's function could be selectively targeted to colonic tumors to slow their growth.
Materials and methods
Cell culture, transfections and cell growth assays
The human colon carcinoma cell lines HT-29 and WiDr were obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in McCoy's 5A medium (HT-29 cells) or Eagle's minimum essential medium containing 0.1 mM non-essential amino acids and 1.0 mM sodium pyruvate (WiDr cells) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), unless otherwise stated. NCM460 human colon epithelial cells (INCELL, San Antonio, TX, USA) were maintained in M3:10 medium (INCELL). Methods were previously described for transient and stable transfections, cell growth assays (Chang et al., 1998 (Chang et al., , 2001 (Chang et al., , 2002 Mamidipudi et al., 2004a, b) and peptide incubations (Miller et al., 2004) . Cell proliferation assays: equal volumes of cells were collected in fresh media containing 10% Alamar Blue, and absorbance was measured hourly at a wavelength of 562 and 595 nm for 7-10 h. Reduction of Alamar Blue was calculated from absorbance, according to the manufacturer's protocol (Biosource, Camarillo, CA, USA).
Reagents
Plasmids pcDNA3-GFP, pcDNA3-GFP-RACK1, pcDNA3-GFP-RACK1Y228F/Y246F, pcDNA3, pcDNA3-HA-RACK1, pcDNA3-HA-RACK1Y228F/Y246F and pc-src Y527F-neoMLV were described previously (Cartwright et al., 1987; Chang et al., 1998 Chang et al., , 2001 Chang et al., , 2002 Mamidipudi et al., 2004a, b) . Human src siRNA plasmids (Paul et al., 2002) were constructed according to the manufacturer's recommendations (Imgenex, San Diego, CA, USA). The target sequences of siRNA-5 and siRNA-6 are 639-660 and 1076-1098bp, respectively (human src accession # NM_004383). A BLAST search confirmed that the targeted sequences and those of a scrambled control (IMG 800-6; Imgenex) matched no other human cDNA sequence in GenBank. Briefly, for each siRNA plasmid, two complementary oligonucleotides were annealed and ligated into pSuppressor. The resulting short RNA transcript is predicted to have a six-nucleotide loop. RACK1 siRNA (SMARTpool) and non-targeting siRNA were commercially available (Dharmacon, Lafayette, CO, USA). Peptides b-agonist (pseudo-bRACK1 or -cbRACK1; SVEIWD, derived from the C2 regions of bPKC), bC2-4 (SLNPEWNET, corresponding to amino acids 218-216 in bPKC) or bIIV5-3 (QEVIRN, corresponding to amino acids 645-650 in bIIPKC) were conjugated to carrier peptide derived from the TAT protein (TAT 47-57 : YGRKKRRQRRR) for delivery into cells Stebbins and Mochly-Rosen, 2001 ).
Immunoblot analysis, antibodies and in vitro protein kinase assays Lysates of total cellular proteins or immunoprecipitates were analysed by protein immunoblotting after sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) with the specified rabbit or goat polyclonal or mouse monoclonal antibody, as described (Mamidipudi et al., 2004a, b) . Primary antibodies included mouse monoclonal antibodies to Src (MAb 327), RACK1, GFP (JL-8), Stat3, Stat3 pY705, Kip1/ p27, phosphotyrosine (Py20) (Transduction Laboratories, Lexington, KY, USA), c-Myc (9E10), CDK2 (D-12), Vav (D-7), Cdc2/CDK1 p34 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and pRb (G3-245 (Pharmingen, San Diego, CA, USA) for RACK1 overexpression studies, and pRb 4H1 (Cell Signaling Technology, Beverly, MA, USA) for Src depletion studies). Other primary antibodies included rabbit polyclonal antisera to CDK4 (C-22), cyclin D1 (M-20), E2F1 (KH95), cyclin B and Sam68 (Santa Cruz Biotechnology). Methods to assess the phosphorylating activity of Src, CDK4, CDK2 and CDK1 by kinase assays in vitro have been described (Mamidipudi et al., 2004a, b) .
Flow cytometric analysis for DNA content and Ki-67 expression For the analysis of G 1 /S progression, HT-29 transfectants were synchronized in G 1 , released into G 1 and analysed for cellular DNA content as described (Mamidipudi et al., 2004a, b) . For the analysis of Ki-67 expression (Fleury et al., 2000) , 10 6 asynchronous HT-29 transfectants were fixed in 70% ethanol, collected by low-speed centrifugation, resuspended in phosphate-buffered saline (PBS) containing fluorescein isothiocyanate (FITC)-conjugated anti-Ki-67 or mouse IgG1, and incubated for 30 min at room temperature in the dark according to the manufacturer's protocol (Pharmingen) before staining with propidium iodide (PI; Sigma, St Louis, MO, USA). Cells (10 4 ) were analysed by FACScan cell sorting (Becton Dickinson, San Jose, CA, USA). Dot plots were prepared using FlowJo software (Tree Star, San Carlos, CA, USA). RACK1 and Src immunoblot analyses performed on lysate from parallel plates of cells to those used for measuring cellular DNA content and Ki-67 flow cytometry analyses demonstrated consistent levels of GFP-RACK1, HA-RACK1 expression or Src depletion for all transfections. For the analysis of G 2 /M transition, cells were treated with aphidicolin RACK1 regulates colonic cell growth V Mamidipudi et al
